Emalex Biosciences Is A Biopharmaceutical Company Dedicated To Developing Innovative Treatments For Central Nervous Systemcnsdisordersfounded In 2018 As Part Of Paragon Biosciencesthe Company Focuses On Addressing Chronic Neurological Conditions Through Scientific Innovation Emalex Specializes In Movement And Fluency Disorderswith Its Lead Candidateecopipamcurrently In Late Stage Clinical Development For Tourette Syndromethe Company Prioritizes Late Stage Clinical Studies To Evaluate The Safety And Efficacy Of Ecopipamin 2022Emalex Secured $250 Million In Funding To Support Its Investigational Therapiesthe Leadership Teamincluding Chief Medical Officer Frederick Munschauerm D Brings Extensive Experience In Neurology And Emphasizes Translational Research In 2024Emalex Was Recognized As The Aeoeneuroscience Therapeutics Company Of The Yearae By Biotech Breakthrough For Its Advancements In Cns Drug Developmentthe Company Aims To Improve The Lives Of Patients With Tourette Syndrome And Other Cns Movement Disorders Through Collaboration With Clinical Researchers And Healthcare Providers
No conferences found for this company.
| Company Name | Emalex Biosciences Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
